Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J.

Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.

PMID:
30537516
2.

Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome.

Grupp K, Hofmann B, Kutup A, Bachmann K, Bogoevski D, Melling N, Uzunoglu FG, El Gammal AT, Koop C, Simon R, Steurer S, Krech T, Burdak-Rothkamm S, Jacobsen F, Sauter G, Izbicki J, Wilczak W.

BMC Cancer. 2018 Nov 12;18(1):1106. doi: 10.1186/s12885-018-5032-z.

3.

Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.

Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Büscheck F, Krech T, Lennartz M, Harms L, Leleu D, Ahrens M, Ingwerth S, Günther CT, Koop C, Simon R, Jacobsen F, Tsourlakis MC, Chirico V, Höflmayer D, Vettorazzi E, Haese A, Steuber T, Salomon G, Michl U, Budäus L, Tilki D, Thederan I, Fraune C, Göbel C, Henrich MC, Juhnke M, Möller K, Bawahab AA, Uhlig R, Adam M, Weidemann S, Beyer B, Huland H, Graefen M, Sauter G, Schlomm T.

Eur Urol. 2018 Sep;74(3):376-386. doi: 10.1016/j.eururo.2018.05.034. Epub 2018 Jun 13.

PMID:
29908878
4.

PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.

Lotan TL, Heumann A, Rico SD, Hicks J, Lecksell K, Koop C, Sauter G, Schlomm T, Simon R.

Oncotarget. 2017 Jul 10;8(39):65566-65576. doi: 10.18632/oncotarget.19217. eCollection 2017 Sep 12.

5.

High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.

Steurer S, Rico SD, Simon R, Minner S, Tsourlakis MC, Krech T, Koop C, Graefen M, Heinzer H, Adam M, Huland H, Schlomm T, Sauter G, Lumiani A.

BJU Int. 2017 Sep;120(3):365-376. doi: 10.1111/bju.13840. Epub 2017 Apr 11.

6.

Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.

Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, Schlomm T.

Oncotarget. 2017 Jan 10;8(2):3761. doi: 10.18632/oncotarget.14557. No abstract available.

7.

βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.

Hinsch A, Chaker A, Burdelski C, Koop C, Tsourlakis MC, Steurer S, Rink M, Eichenauer TS, Wilczak W, Wittmer C, Fisch M, Simon R, Sauter G, Büschek F, Clauditz T, Minner S, Jacobsen F.

Hum Pathol. 2017 Mar;61:210-220. doi: 10.1016/j.humpath.2016.11.005. Epub 2016 Dec 24.

PMID:
28025079
8.

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.

Lebok P, Roming M, Kluth M, Koop C, Özden C, Taskin B, Hussein K, Lebeau A, Witzel I, Wölber L, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech RH, von der Assen A, Burandt E.

Oncotarget. 2016 Dec 6;7(49):81322-81331. doi: 10.18632/oncotarget.13227.

9.

p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.

Burdelski C, Dieckmann T, Heumann A, Hube-Magg C, Kluth M, Beyer B, Steuber T, Pompe R, Graefen M, Simon R, Minner S, Tsourlakis MC, Koop C, Izbicki J, Sauter G, Krech T, Schlomm T, Wilczak W, Lebok P.

Tumour Biol. 2016 Sep;37(9):12655-12663. Epub 2016 Jul 21.

PMID:
27444279
10.

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer.

Lennartz M, Minner S, Brasch S, Wittmann H, Paterna L, Angermeier K, Öztürk E, Shihada R, Ruge M, Kluth M, Koop C, Wilczak W, Krech T, Lebok P, Wittmer C, Heinzer H, Steuber T, Adam M, Huland H, Graefen M, Haese A, Simon R, Sauter G, Schlomm T.

Clin Cancer Res. 2016 Jun 1;22(11):2802-11. doi: 10.1158/1078-0432.CCR-15-0635. Epub 2016 Jan 26.

11.

Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer.

Melling N, Taskin B, Hube-Magg C, Kluth M, Minner S, Koop C, Grob T, Graefen M, Heinzer H, Tsourlakis MC, Izbicki J, Wittmer C, Huland H, Simon R, Wilczak W, Sauter G, Steurer S, Schlomm T, Krech T.

Prostate. 2016 Feb 15;76(3):259-72. doi: 10.1002/pros.23120. Epub 2015 Nov 2.

PMID:
26764246
12.

Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.

Pust A, Kylies D, Hube-Magg C, Kluth M, Minner S, Koop C, Grob T, Graefen M, Salomon G, Tsourlakis MC, Izbicki J, Wittmer C, Huland H, Simon R, Wilczak W, Sauter G, Steurer S, Krech T, Schlomm T, Melling N.

Hum Pathol. 2016 Feb;48:102-10. doi: 10.1016/j.humpath.2015.09.026. Epub 2015 Oct 22.

PMID:
26614400
13.

Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.

Melling N, Thomsen E, Tsourlakis MC, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Wilczak W, Huland H, Simon R, Schlomm T, Steurer S, Krech T.

Carcinogenesis. 2015 Nov;36(11):1333-40. doi: 10.1093/carcin/bgv137. Epub 2015 Sep 21.

PMID:
26392259
14.

Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.

Burdelski C, Kleinhans S, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Marx A, Sauter G, Wittmer C, Huland H, Simon R, Schlomm T, Steurer S.

Int J Cancer. 2016 Mar 1;138(5):1199-206. doi: 10.1002/ijc.29860. Epub 2015 Oct 1.

15.

Diverse expression patterns of the EMT suppressor grainyhead-like 2 (GRHL2) in normal and tumour tissues.

Riethdorf S, Frey S, Santjer S, Stoupiec M, Otto B, Riethdorf L, Koop C, Wilczak W, Simon R, Sauter G, Pantel K, Assmann V.

Int J Cancer. 2016 Feb 15;138(4):949-63. doi: 10.1002/ijc.29841. Epub 2015 Sep 25.

16.

Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.

Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, Schlomm T.

Oncotarget. 2015 Sep 29;6(29):27966-79. doi: 10.18632/oncotarget.4626. Erratum in: Oncotarget. 2017 Jan 10;8(2):3761.

17.

High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer.

Melling N, Harutyunyan L, Hube-Magg C, Kluth M, Simon R, Lebok P, Minner S, Tsourlakis MC, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Steurer S, Izbicki J, Sauter G, Wilczak W, Schlomm T, Krech T.

PLoS One. 2015 Jul 31;10(7):e0134614. doi: 10.1371/journal.pone.0134614. eCollection 2015.

18.

The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.

Burdelski C, Menan D, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Simon R, Schlomm T, Steurer S, Krech T.

BMC Cancer. 2015 Jul 23;15:538. doi: 10.1186/s12885-015-1555-8.

19.

Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.

Grupp K, Roettger L, Kluth M, Hube-Magg C, Simon R, Lebok P, Minner S, Tsourlakis MC, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Wilczak W, Huland H, Schlomm T, Steurer S, Krech T.

Oncol Rep. 2015 Sep;34(3):1211-20. doi: 10.3892/or.2015.4080. Epub 2015 Jun 25.

PMID:
26134445
20.

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.

Burdelski C, Bujupi E, Tsourlakis MC, Hube-Magg C, Kluth M, Melling N, Lebok P, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Wilczak W, Simon R, Schlomm T, Steurer S, Krech T.

PLoS One. 2015 Jun 1;10(6):e0128525. doi: 10.1371/journal.pone.0128525. eCollection 2015.

Supplemental Content

Loading ...
Support Center